[EN] (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS<br/>[FR] COMPOSÉS D'(HÉTÉRO)ARYL-CYCLOPROPYLAMINE À TITRE D'INHIBITEURS DE LSD1
申请人:ORYZON GENOMICS SA
公开号:WO2013057322A1
公开(公告)日:2013-04-25
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
Synthesis, reactions and structural features of monofluorinated cyclopropanecarboxylates
作者:Günter Haufe、Thomas C. Rosen、Oliver G.J. Meyer、R. Fröhlich、Kari Rissanen
DOI:10.1016/s0022-1139(02)00040-4
日期:2002.4
Monofluorinated cyclopropanecarboxylates are available in racemic or optically active form by transition metal-catalyzed reactions of vinylfluorides with diazoacetates. From α-fluorostyrene and tert-butyl diazoacetate in the presence of 2 mol% of an enantiopure bis(oxazoline) copper complex, a 81:19 mixture of tert-butyl trans- and cis-2-fluoro-2-phenylcyclopropanecarboxylates was obtained with high
respectively, were obtained. An advantage of the latter protocol is the in situ formation of ethyldiazoacetate from ethyl glycinate hydrochloride in aqueous solution by diazotation avoiding the in-substance application of the potentially explosive ethyldiazoacetate. Accordingly, a series of diastereoisomeric ethyl 2-aryl-2-fluoro-cyclopropane carboxylates was synthesized from p- or m-substituted α-fluorostyrenes
(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS
申请人:ORYZON GENOMICS, S.A.
公开号:US20150119396A9
公开(公告)日:2015-04-30
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and theft use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.